Clinical trials: Neoplasia Prostate
Prostate Cancer
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer
As the most common carcinoma in men, prostate cancer is a significant tumor entity in oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent therapy alternative in the non-metastatic primary…
- Trial name
- SMILE (NCT04845503)
- Testing
- MR-guided Radiotherapy
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Prostate Cancer
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT).
- Trial name
- NCT07210086
- Testing
- ADT, ARSI, No ADT/ARSI -decline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
This study tests the safety and tolerability of autologous anti-PSMA gene-modified T cells (designer T cells) in hormone refractory prostate cancer.
- Trial name
- NCT00664196
- Testing
- Gene Modified T Cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roger Williams Medical Center
Prostate Cancer
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early detection and improved local therapies a large number of men will be cured.
- Trial name
- NCT01417182
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Localized Breast Cancer, Localized Prostate Cancer
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
Participants will be diagnosed with localized prostate or breast cancer and be scheduled to undergo external beam radiation therapy.
- Conditions
- Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
- Trial name
- NCT00651417
- Testing
- Organic Germanium
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Arizona Oncology Services
Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer.
- Trial name
- PrTK03 (NCT01436968)
- Testing
- Aglatimagene besadenovec + valacyclovir
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 711 people
- Sponsor
- Candel Therapeutics, Inc.
Prostate Cancer
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer
This is a single-arm, open label phase II trial of the investigational agent, Ara-C (cytarabine), in patients diagnosed with hormone refractory prostate cancer whose disease has progressed on or deemed not suitable for standard…
- Trial name
- SLAP (NCT00480090)
- Testing
- Cytarabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Metastatic Castration-Resistant Prostate Cancer
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria.
- Trial name
- NCT04986423
- Testing
- ZEN003694, Enzalutamide
- Where
- 31 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Zenith Epigenetics
Breast Cancer, Colorectal Cancer
Physical Training and Cancer-a Multicenter Clinical Trial
Excessive tiredness (fatigue) is a common problem in cancer patients and can affect quality of life negatively. There is limited knowledge about the physical mechanisms that cause fatigue, and there is no medical treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- Phys-Can (NCT02473003)
- Testing
- high intensity exercise, low/medium intensity exercise, Behavioral medicine strategies
- Volunteers
- 600 people
- Sponsor
- Uppsala University
Prostate Cancer
Prostate Cancer Upgrading Reference Set
Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence…
- Trial name
- NCT02189486
- Where
- United States
- Volunteers
- 382 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Combination of 68Ga-PSMA PET Data With Magnetic Resonance Spectroscopy Data (MRS) for Evaluating Prostate Cancer
Prostate cancer is the second most common cancer among man and the fourth most occurring over all . Characterization and management of the diagnosed prostate cancer is a challenging task due to its clinically and morphologically…
- Trial name
- NCT04154280
- Testing
- PET/MR scan
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prostate Cancer
Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate
RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue.
- Trial name
- NCT00030290
- Testing
- high-intensity focused ultrasound ablation
- Where
- United States
- Sponsor
- Focus Surgery
Prostate Cancer
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate cancer and neuro-endocrine differentiation.
- Trial name
- NCT00973882
- Testing
- Carboplatin, Etoposide
- Where
- 11 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Prostate Cancer
Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Background: Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these…
- Trial name
- NCT01867424
- Testing
- Eovist
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
High-risk Prostate Cancer
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
Recent evidence suggests that both standard-time and delayed-time [⁶⁸Ga]Ga-PSMA PET acquisitions can reveal clinically relevant findings, and neither phase should be excluded a priori in routine practice.
- Trial name
- SPIR202302 (NCT07357259)
- Testing
- Intervention Group
- Where
- Italy
- Volunteers
- 244 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sarcopenia, Prostate Cancer
Changes in Body Composition With Patients Under Androgen Deprivation Therapy
This study aimed to evaluate the correlation of change in body composition and oncological outcomes of prostate cancer patients under androgen deprivation therapy(ADT).
- Trial name
- NCT04037488
- Testing
- Inbody 320
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Prostate Cancer
Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer
Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)
- Trial name
- CHEMOPROST (NCT02869282)
- Testing
- Blood samples, Urine samples
- Where
- France
- Sponsor
- Institut Bergonié
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.